Efficacy and Safety of Nab-Paclitaxel Plus S-1 versus Nab-Paclitaxel Plus Gemcitabine for First-Line Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma

OBJECTIVE: Nab-paclitaxel plus gemcitabine (nab-P/G) has been established as a standard first-line treatment in metastatic pancreatic ductal adenocarcinoma (PDAC). S-1, as an oral fluoropyrimidine derivative, demonstrated effective for PDAC. This study aimed to evaluate the efficacy and safety of fi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zong, Yuan, Peng, Zhi, Wang, Xicheng, Lu, Ming, Shen, Lin, Zhou, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733895/
https://www.ncbi.nlm.nih.gov/pubmed/33328763
http://dx.doi.org/10.2147/CMAR.S263773

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733895/
https://www.ncbi.nlm.nih.gov/pubmed/33328763
http://dx.doi.org/10.2147/CMAR.S263773

Ejemplares similares